Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Review
. 2015 Nov 20:8:129.
doi: 10.1186/s13045-015-0224-3.

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Shundong Cang  1 , Chaitanya Iragavarapu  2 , John Savooji  2 , Yongping Song  3 , Delong Liu  4
Affiliations
Review

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Shundong Cang (VSports在线直播) et al. J Hematol Oncol. .

Abstract

With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion VSports手机版. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins. .

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structures of BCL-2 family proteins. According to the BH domains, the BCL-2 family proteins can be categorized into three subsets. BH4-containing BCL-2 and related BCL-XL, BCL-w, MCL-1, A1(BFL-1), and Boo are anti-apoptotic proteins. The remaining two subsets (BAX and Bik subgroups) do not have a BH4 domain and are pro-apoptotic proteins
See this image and copyright information in PMC

References

    1. Akinleye A, Avvaru P, Furqan M, Song Y, Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88. doi: 10.1186/1756-8722-6-88. - DOI (V体育安卓版) - PMC - PubMed
    1. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):27. doi: 10.1186/1756-8722-6-27. - DOI - PMC - PubMed
    1. Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6(1):90. doi: 10.1186/1756-8722-6-90. - DOI - PMC - PubMed
    1. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013;1(1):5. doi: 10.1186/2050-7771-1-5. - DOI (VSports手机版) - PMC - PubMed
    1. Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: from bench to bedside. J Hematol Oncol. 2013;6(1):30. doi: 10.1186/1756-8722-6-30. - DOI - PMC - PubMed

VSports手机版 - MeSH terms